← Eichor
Study identifier: NCT06999980 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Condition: Cutaneous Melanoma · Mucosal Melanoma  ·  Sponsor: Melanoma Institute Australia

PhasePhase 2
Planned participants494
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Monica Osorio  ·  +612 9911 7296  ·  Monica.Osorio@melanoma.org.au

Always discuss trial participation with your own doctor first.

Locations (1)

Melanoma Institute AustraliaWollstonecraft, New South Wales, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06999980